Recent Finacing
Recent Raise
Myelo Therapeutics (Berlin/Dresden) develops Myelo001, an oral once-daily tablet to prevent chemotherapy‑induced neutropenia and is conducting a randomized, double‑blind Phase II multicenter MyeloConcept trial in breast cancer.
Focus Areas
Recent Investors
Funding round
Investors
